New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Magnolia Neurosciences is raising $17,909,091.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Thong Le played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Magnolia Neurosciences

Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company. With its $31 million Series A financing announced in August of 2018, Magnolia Neurosciences aims to discover and develop proprietary, potent, and selective therapies for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions.

To learn more about Magnolia Neurosciences, visit http://magnolianeurosciences.com/

Contact:
Thong Le, President and Chief Executive Officer
646-828-5990

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved